Skip to main content
Top
Published in: Clinical Rheumatology 9/2014

01-09-2014 | Original Article

Remission criteria and activity indices in psoriatic arthritis

Authors: M. L. Acosta Felquer, L. Ferreyra Garrott, J. Marin, E. Catay, M. Scolnik, V. Scaglioni, S. Ruta, J. Rosa, E. R. Soriano

Published in: Clinical Rheumatology | Issue 9/2014

Login to get access

Abstract

Remission criteria and activity indices used in rheumatoid arthritis (RA) are often applied in psoriatic arthritis (PsA). Some new indices have been specifically developed for PsA. Our objective was to evaluate the performance of different remission criteria and activity indices in PsA. This is a cross-sectional study that includes consecutive patients with PsA. Information necessary to complete the following indices was captured: Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic Arthritis Screening and Evaluation (PASE), Disease Activity Index for Psoriatic Arthritis (DAPSA), Disease Activity Score in 28 Joints (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), and American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) Boolean RA remission criteria. Patients were classified according to activity categories (remission, low, medium, or high disease activity). Correlation between indices was established. Fifty-five patients were included. Mean age was 53 years (SD = 12), and 35 (63.6 %) were males. Mean PsA disease duration was 5.9 years (SD = 8.5), and mean psoriasis duration was 15.9 (SD = 12.6). We found important differences in the percentage of patients classified as in remission by applying different remission criteria: DAS28 = 33 % (95 % confidence interval (CI) 20–45) vs ACR/EULAR = 4 % (95 % CI 1–17). Particularly, DAS28 and minimal disease activity seemed to be less stringent in PsA than the other indices. Of the specific PsA indices evaluated, CPDAI showed the poorest correlation with all the other activity measurements, although differences were not statistically significant in most cases. Disease activity in PsA is measured by many different indices. In spite they all showed good correlations between them, they classified different patients in different disease status.
Literature
1.
go back to reference Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W (2004) Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 50(1):24–35. doi:10.1002/art.11417 PubMedCrossRef Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W (2004) Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 50(1):24–35. doi:10.​1002/​art.​11417 PubMedCrossRef
2.
go back to reference Kavanaugh A, Cassell S (2005) The assessment of disease activity and outcomes in psoriatic arthritis. Clin Exp Rheumatol 23(5 Suppl 39):S142–S147PubMed Kavanaugh A, Cassell S (2005) The assessment of disease activity and outcomes in psoriatic arthritis. Clin Exp Rheumatol 23(5 Suppl 39):S142–S147PubMed
3.
go back to reference Mease PJ, Antoni CE, Gladman DD, Taylor WJ (2005) Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 64(Suppl 2):ii49–ii54PubMedCentralPubMed Mease PJ, Antoni CE, Gladman DD, Taylor WJ (2005) Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 64(Suppl 2):ii49–ii54PubMedCentralPubMed
4.
go back to reference Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727–735PubMedCrossRef Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727–735PubMedCrossRef
5.
go back to reference van der Heijde DM, van’t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49(11):916–920PubMedCentralPubMedCrossRef van der Heijde DM, van’t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49(11):916–920PubMedCentralPubMedCrossRef
6.
go back to reference Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, Helliwell P, FitzGerald O (2011) Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 70(2):272–277. doi:10.1136/ard.2010.129379 PubMedCrossRef Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, Helliwell P, FitzGerald O (2011) Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 70(2):272–277. doi:10.​1136/​ard.​2010.​129379 PubMedCrossRef
7.
8.
go back to reference Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA (2013) The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 72(6):986–991. doi:10.1136/annrheumdis-2012-201341 PubMedCrossRef Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA (2013) The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 72(6):986–991. doi:10.​1136/​annrheumdis-2012-201341 PubMedCrossRef
10.
go back to reference Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Canete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewe R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P, European League Against R (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71(1):4–12. doi:10.1136/annrheumdis-2011-200350 PubMedCrossRef Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Canete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewe R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P, European League Against R (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71(1):4–12. doi:10.​1136/​annrheumdis-2011-200350 PubMedCrossRef
11.
go back to reference Lubrano E, Soriano E, FitzGerald O (2013) Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis? Clin Exp Rheumatol 31(4 Suppl 78):S54–S58PubMed Lubrano E, Soriano E, FitzGerald O (2013) Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis? Clin Exp Rheumatol 31(4 Suppl 78):S54–S58PubMed
12.
go back to reference Gladman DD, Hing EN, Schentag CT, Cook RJ (2001) Remission in psoriatic arthritis. J Rheumatol 28(5):1045–1048PubMed Gladman DD, Hing EN, Schentag CT, Cook RJ (2001) Remission in psoriatic arthritis. J Rheumatol 28(5):1045–1048PubMed
14.
go back to reference Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, Salvarani C (2009) Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs. J Rheumatol Suppl 83:78–80. doi:10.3899/jrheum.090234 PubMedCrossRef Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, Salvarani C (2009) Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs. J Rheumatol Suppl 83:78–80. doi:10.​3899/​jrheum.​090234 PubMedCrossRef
15.
go back to reference Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, Salvarani C (2008) Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology 47(6):872–876. doi:10.1093/rheumatology/ken059 PubMedCrossRef Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, Salvarani C (2008) Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology 47(6):872–876. doi:10.​1093/​rheumatology/​ken059 PubMedCrossRef
16.
go back to reference Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M, Lindqvist UR (2013) Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. doi:10.1136/annrheumdis-2012-201972 Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M, Lindqvist UR (2013) Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. doi:10.​1136/​annrheumdis-2012-201972
17.
go back to reference Lindqvist UR, Alenius GM, Husmark T, Theander E, Holmstrom G, Larsson PT, Psoriatic Arthritis Group of the Society for R (2008) The Swedish early psoriatic arthritis register—2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 35(4):668–673PubMed Lindqvist UR, Alenius GM, Husmark T, Theander E, Holmstrom G, Larsson PT, Psoriatic Arthritis Group of the Society for R (2008) The Swedish early psoriatic arthritis register—2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 35(4):668–673PubMed
18.
go back to reference Kavanaugh A, Fransen J (2006) Defining remission in psoriatic arthritis. Clin Exp Rheumatol 24(6 Suppl 43):S083–S087 Kavanaugh A, Fransen J (2006) Defining remission in psoriatic arthritis. Clin Exp Rheumatol 24(6 Suppl 43):S083–S087
20.
go back to reference Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673PubMedCrossRef Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673PubMedCrossRef
21.
go back to reference Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M, American College of R, European League Against R (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63(3):573–586. doi:10.1002/art.30129 PubMedCentralPubMedCrossRef Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M, American College of R, European League Against R (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63(3):573–586. doi:10.​1002/​art.​30129 PubMedCentralPubMedCrossRef
22.
go back to reference Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70(3):404–413. doi:10.1136/ard.2011.149765 PubMedCrossRef Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70(3):404–413. doi:10.​1136/​ard.​2011.​149765 PubMedCrossRef
24.
go back to reference Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA (2007) The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 57(4):581–587PubMedCrossRef Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA (2007) The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 57(4):581–587PubMedCrossRef
25.
go back to reference Ferreyra Garrott LG, Soriano ER, Rosa JE, Navarta DA, Saucedo C, Scolnik M, Bedran Z, Sabelli M, Garcia MV, Anselmi C, Galimberti R, Catoggio LJ, Husni ME, Qureshi AA (2013) Validation in Spanish of a screening questionnaire for the detection of psoriatic arthritis in patients with psoriasis. Rheumatology 52(3):510–514. doi:10.1093/rheumatology/kes306 PubMedCrossRef Ferreyra Garrott LG, Soriano ER, Rosa JE, Navarta DA, Saucedo C, Scolnik M, Bedran Z, Sabelli M, Garcia MV, Anselmi C, Galimberti R, Catoggio LJ, Husni ME, Qureshi AA (2013) Validation in Spanish of a screening questionnaire for the detection of psoriatic arthritis in patients with psoriasis. Rheumatology 52(3):510–514. doi:10.​1093/​rheumatology/​kes306 PubMedCrossRef
27.
go back to reference van Gestel AM, Prevoo ML, van’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39(1):34–40PubMedCrossRef van Gestel AM, Prevoo ML, van’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39(1):34–40PubMedCrossRef
28.
go back to reference Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42(2):244–257PubMedCrossRef Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42(2):244–257PubMedCrossRef
29.
go back to reference Citera G, Arriola MS, Maldonado-Cocco JA, Rosemffet MG, Sanchez MM, Goni MA, Spindler A, Lucero E, Berman A (2004) Validation and crosscultural adaptation of an argentine spanish version of the health assessment questionnaire disability index. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 10(3):110–115. doi:10.1097/01.rhu.0000128732.58292.cd Citera G, Arriola MS, Maldonado-Cocco JA, Rosemffet MG, Sanchez MM, Goni MA, Spindler A, Lucero E, Berman A (2004) Validation and crosscultural adaptation of an argentine spanish version of the health assessment questionnaire disability index. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 10(3):110–115. doi:10.​1097/​01.​rhu.​0000128732.​58292.​cd
30.
go back to reference Coates LC, Fitzgerald O, Mease PJ, Gladman DD, Strand V, Goel N, Campbell I, Krueger G, McHugh NJ, Helliwell PS (2014) Development of a Disease Activity and Responder Index for Psoriatic Arthritis—report of the psoriatic arthritis module at OMERACT 11. J Rheumatol 41:782–791. doi:10.3899/jrheum.131250 PubMedCrossRef Coates LC, Fitzgerald O, Mease PJ, Gladman DD, Strand V, Goel N, Campbell I, Krueger G, McHugh NJ, Helliwell PS (2014) Development of a Disease Activity and Responder Index for Psoriatic Arthritis—report of the psoriatic arthritis module at OMERACT 11. J Rheumatol 41:782–791. doi:10.​3899/​jrheum.​131250 PubMedCrossRef
31.
go back to reference Coates LC, Navarro-Coy N, Brown SR, Brown S, McParland L, Collier H, Skinner E, Law J, Moverley A, Pavitt S, Hulme C, Emery P, Conaghan PG, Helliwell PS (2013) The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 14:101. doi:10.1186/1471-2474-14-101 PubMedCentralPubMedCrossRef Coates LC, Navarro-Coy N, Brown SR, Brown S, McParland L, Collier H, Skinner E, Law J, Moverley A, Pavitt S, Hulme C, Emery P, Conaghan PG, Helliwell PS (2013) The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 14:101. doi:10.​1186/​1471-2474-14-101 PubMedCentralPubMedCrossRef
Metadata
Title
Remission criteria and activity indices in psoriatic arthritis
Authors
M. L. Acosta Felquer
L. Ferreyra Garrott
J. Marin
E. Catay
M. Scolnik
V. Scaglioni
S. Ruta
J. Rosa
E. R. Soriano
Publication date
01-09-2014
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 9/2014
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2626-y

Other articles of this Issue 9/2014

Clinical Rheumatology 9/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.